Atopic Dermatitis Connect
  • Saved

made a Post

3yr
Topical JAK Inhibitors for Atopic Dermatitis

Atopic dermatitis (AD), also known as atopic eczema, is a chronic, pruritic, relapsing inflammatory dermatological condition. Early disease management includes moisturizers, avoiding the factors that trigger AD, and patient education. Treatment mainly aims at reducing itch and inflammation, eliminating flare-ups, and reducing side effects.



Topical agents are considered as a primary treatment for mild to moderate AD and include topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and phosphodiesterase 4 (PDE4) inhibitor. More recently, the first topical selective Janus kinase (JAK)1/JAK2 inhibitor has been approved for use in patients with mild to moderate disease.




  • How will the availability of a topical selective JAK impact your use of TCS, TCI, or PDE4 in mild to moderate AD patients?

  • In which types of patients do you foresee the greatest utility of a topical selective JAK in the treatment of mild to moderate AD patients?


  • 3yr
    Topical JAKs will play a significant role in treating AD patients of all severities because of their efficacy that appears to be substantially better than other non-steroid topicals like TCIs Show More
  • 3yr
    I don't think topical JAKs have been a game changer in mild to moderate AD - unfortunately in part because most insurance plans don't seem to cover them well without Show More

Show More Comments

  • Saved

made a Post

3yr
Topical JAK Inhibitors for Atopic Dermatitis

Atopic dermatitis (AD), also known as atopic eczema, is a chronic, pruritic, relapsing inflammatory dermatological condition. Early disease management includes moisturizers, avoiding the factors that trigger AD, and patient education. Treatment mainly aims at reducing itch and inflammation, eliminating flare-ups, and reducing side effects.



Topical agents are considered as a primary treatment for mild to moderate AD and include topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and phosphodiesterase 4 (PDE4) inhibitor. More recently, the first topical selective Janus kinase (JAK)1/JAK2 inhibitor has been approved for use in patients with mild to moderate disease.




  • How will the availability of a topical selective JAK impact your use of TCS, TCI, or PDE4 in mild to moderate AD patients?

  • In which types of patients do you foresee the greatest utility of a topical selective JAK in the treatment of mild to moderate AD patients?


  • 3yr
    Topical JAKs will play a significant role in treating AD patients of all severities because of their efficacy that appears to be substantially better than other non-steroid topicals like TCIs Show More
  • 3yr
    I don't think topical JAKs have been a game changer in mild to moderate AD - unfortunately in part because most insurance plans don't seem to cover them well without Show More

Show More Comments

  • Saved

3yr
The IL-4/-13 Axis and Its Blocking in the Treatment of Atopic Dermatitis

The IL-4/-13 Axis and Its Blocking in the Treatment of Atopic Dermatitis

Source : https://doi.org/10.3390/jcm11195633

Atopic dermatitis (AD) is a common inflammatory skin disease with a complex pathophysiology, intertwining immune dysregulation, epidermal barrier dysfunction, IgE sensitization, environmental factors and genetic predisposition. It has been recently...


Conclusion: Advances in understanding IL-4/IL-13 pathway have opened the way for the development of novel therapeutic agents that target important steps of those signaling cascades. Most importantly, monoclonal antibodies that inhibit the IL-4/IL-13 pathway have revolutionized the treatment of moderate-to-severe AD. In this context, JAK...

  • 3yr
    A number of lines of experimental evidence over the years have suggested that IL-4 and -13 are key cytokines of the Th2 immune system and are important mediators of atopic Show More
  • 3yr
    Clearly, dupixent has revolutionized the treatment of moderate to severe AD. I am also seeing excellent results using rinvoq in AD, and I suspect that the JAK-STAT effect on the Show More
  • Saved

3yr
Ultra-high frequency ultrasound detection of the dermo-epidermal junction: Its potential role in dermatology - PubMed

Ultra-high frequency ultrasound detection of the dermo-epidermal junction: Its potential role in dermatology - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36017602/

Traditional high-frequency ultrasound (HFUS; 20 MHz) is a non-invasive method used to study skin in vivo but is not able to measure skin thickness accurately and to identify the dermal-epidermal...


Conclusion: Ultra-high frequency ultrasound is a useful technique in the field of dermatology which can provide critical information to complement clinical data.

  • Saved

3yr
Impact of a decade of research into atopic dermatitis - PubMed

Impact of a decade of research into atopic dermatitis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36162801/

The last decade has seen an unprecedented pace of change, particularly of clinical research in atopic dermatitis (AD). This review summarizes some key discoveries. Over the last 10 years, nearly...


Discussion: The aim of this Clinical Commentary within the tenth Anniversary theme issue of the Journal 47 is to review the most clinically relevant advances in atopic dermatitis (AD) over the last decade.